We are live on
!
Find out more
Puma Biotechnology
PBYI
PBYI
158 hedge funds and large institutions have $1.32B invested in Puma Biotechnology in 2019 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 52 increasing their positions, 44 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
86% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 22
85% more capital invested
Capital invested by funds: $715M → $1.32B (+$609M)
65% more call options, than puts
Call options by funds: $33.2M | Put options by funds: $20.1M
18% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 44
12% more funds holding
Funds holding: 141 → 158 (+17)
3.55% less ownership
Funds ownership: 92.29% → 88.74% (-3.5%)
Holders
158
Holders Change
+17
Holders Change %
+12.06%
% of All Funds
3.42%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
41
Increased
52
Reduced
44
Closed
22
Calls
$33.2M
Puts
$20.1M
Net Calls
+$13.1M
Net Calls Change
+$18.4M
Top Buyers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$79.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$24M |
| 3 |
D.E. Shaw & Co
New York
|
+$13M |
| 4 |
FAM
Fred Alger Management
New York
|
+$11.3M |
| 5 |
Goldman Sachs
New York
|
+$11.2M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$33.3M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$26.5M |
| 3 |
MAM
Melqart Asset Management
London,
United Kingdom
|
-$23.6M |
| 4 |
O
OrbiMed
New York
|
-$22M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$15.7M |
